Open navigation
Search
Borys Danevych
Partner

Borys Danevych

Global Co-Head of Life Sciences and Healthcare | CEE Head of Life Sciences and Healthcare

Kyiv, Ukraine
Languages
  • English
  • Ukrainian
Social media

Borys Danevych is the Global Co-Head of the CMS Life Sciences & Healthcare Group. In this position, he jointly leads an international team of more than 480 lawyers, patent attorneys, scientists and academics’ across CMS.  Borys is also a Partner and Head of Life Sciences & Healthcare practices at CMS Ukraine and the CEE Head of Life Sciences and Healthcare group.

Borys has over 20 years of experience working with international pharmaceutical, biotech, animal health, medtech, consumer product companies, as well as healthcare service providers and health technology organisations. He regularly advises clients on complex regulatory, compliance matters and commercial matters, anti-counterfeiting, pharmaceutical competition and IP, policy dialogue projects and regulatory disputes. Borys also counsels clients on anti-counterfeiting and white-collar criminal investigations in life sciences sector. Borys advised international donor organisations on policy dialogue projects in Ukraine (including significant projects rated to healthcare reforms and pharmaceutical regulations development).

Over the past decade, Borys has been focused on enhancing legislation and regulations in a few pivotal sectors, including pharmaceuticals, medical devices, veterinary products and healthcare services guaranteeing compliance with EU standards and best international practices. Furthermore, his advice has encompassed market access for health technologies, intellectual property, rehabilitation and prosthetics.

As a leading life sciences lawyer in Ukraine, Borys is widely recognised for his work in the sector. Borys is recognised as a “leading partner” supporting life sciences clients in the fields of intellectual property and competition by recent Legal 500 ranking. Borys is also a recommended lawyer in Government Contracts and Life Sciences - Regulatory fields by recent Lexology Index report, by indicating that he "inspires confidence in clients dealing with biotech, medical R&D and healthcare matters".

Awards & Recognitions
01 –
  • Quote
    “I like that he has the habit of informing clients on all recent developments, so we are always up to date, I think this is an interesting and helpful practice.”
    Chambers Europe, 2026
  • Quote
    “He has a very strong commercial awareness with strong understanding of our niche.”
    Chambers Europe, 2026
  • Quote
    “He [Borys Danevych] consistently provides practical, strategic guidance that reflects both legal acumen and real-world business needs.”
    Chambers Europe, 2026
  • Quote
    “Borys Danevych is approachable, responsive, and highly committed to delivering results, which makes collaboration with him both effective and valuable.”
    Chambers Europe, 2026
  • Quote
    “Borys Danevych is a high-calibre professional in healthcare finance and pharma law. His ability to bring together a dedicated, fully multifunctional team of lawyers covers all needs of the demanding clients.”
    Legal 500, 2025

Relevant experience

  • Roche Pharma, a Swiss multinational healthcare holding company, on regulatory, compliance, and competition aspects of regional access and patient support programmes for innovative therapies, ensuring alignment with local laws and competitive standards to support effective healthcare delivery
  • An international pharmaceutical company on significant and high-risk regulatory, pricing & reimbursement, commercial, competition and contractual matters associated with multiple transformations of the pharmaceutical pricing legislation of Ukraine, as well as regarding the Ukrainian competition authority investigation into pharmaceutical wholesale and retail markets
  • A publicly traded American biopharmaceutical company on a wide range of competition law matters related to its operations in Ukraine, including vertical cooperation, pricing, information exchange, necessity to obtain the AMC’s clearance for certain practices, providing strategic counsel on compliance with Ukrainian competition law and mitigation of relevant risks
  • Global clinical development and research services provider on the establishment, transformation and ongoing operation of its business presence in Ukraine. The work included supporting the integration and restructuring of multiple local entities inherited through successive mergers and acquisitions, as well as advising on complex regulatory and compliance matters, interactions with regulatory and enforcement authorities, responses to official inquiries, and tax and customs issues specific to clinical development and clinical trial operations
  • Global medical technology and diagnostics company on multiple complex market access and public procurement matters in Ukraine. This included several major projects involving the public-sector sourcing of sophisticated, innovative diagnostic equipment funded by the Ukrainian government, international donors and foreign governments. Also advised the client on complex compliance, commercial and competition law matters, including the structuring and operation of vertical arrangements with distributors
  • Global leading medical devices company representing in challenging discriminatory tender requirements for a major procurement of sophisticated implantable medical devices. The challenge focused on requirements that placed the client at a competitive disadvantage and restricted its ability to participate effectively in the procurement process
  • Global biopharmaceutical solutions organisation coordinated a pan-European NIS2 compliance project for a global biopharmaceutical solutions and clinical research organisation, covering its local affiliates in more than 20 European jurisdictions. The work involved coordinating local legal advice across the relevant markets and supporting a consistent, group-wide approach to assessing and addressing the organisation’s NIS2 compliance requirements
  • Superhumans Centre on establishment and development of a modern non-profit centre for rehabilitation, prosthetics and reconstructive surgery, including advice on regulatory, commercial and compliance issues, as well as assistance in obtaining USD 25 millions of war risk insurance from the US DFC
  • A large group of leading multinational pharmaceutical companies in several massive criminal investigations on counterfeiting and cross-border trafficking of counterfeit medicines investigated by the National Police, State Border Service, under the supervision of Prosecutor General office. The investigations concerned dozens of global pharmaceutical companies, which products were counterfeited, and/or illegally trafficked in Ukraine
  • Novo Nordisk on competition and regulatory aspects of implementation of a patient support programme, aimed at assisting diabetes patients in Ukraine with access to novelty therapies
  • 11 of top 20 global pharmaceutical companies on regulatory, compliance, commercial, tax and customs aspects of launch and conduct of multi-centre clinical trials in Ukraine, designed and drafted contractual framework (with CROs, study sites, scientific/educational institutions, investigators/study team members, laboratories, diagnostic centres, logistic service providers, insurance companies etc.) 
  • A leading global research-based biopharmaceutical company in a dispute with the Ministry of Health of Ukraine, arisen due to violation of Client’s data exclusivity rights to one of its novel therapies in Ukraine, delivering legal advice and representing Client’s interests in Ukrainian administrative courts, as well as in successful negotiations with the Ukrainian government in the context of an investment dispute
  • Bayer on versatile regulatory, commercial, competition matters, as well as on available market access strategies
  • Janssen, a pharmaceutical division of Johnson & Johnson, on multiple regulatory, compliance, commercial and competition matters, pricing and reimbursement, as well as available market access strategies
  • Lilly on versatile regulatory, commercial, competition, compliance, corporate, employment, IP, tax and customs matters
  • Roche on development of the Anti-Counterfeiting and Anti-Illicit Trade in Medicines Campaign, including conducting in-depth research, drawing up a comprehensive legal report on the current state of Ukrainian anti-counterfeiting and illicit trade legislation, practice of the regulatory and law enforcement agencies, recommending changes in the regulatory, criminal and criminal procedural legislation
  • A global leading animal health company on various complex regulatory, compliance and commercial matters in Ukraine in the context of a massive veterinary legislation reform
  • A top 5 global pharmaceutical company on marketing authorisation in Ukraine of a biosimilar product in light of the then ongoing and later settled patent dispute between the client and the patent holder
  • Shire (now Takeda) on Ukrainian components of USD 2.4 billion oncology business sale to Servier S.A.S., specifically, on transfer of rights for pegaspargase – a treatment for acute lymphoblastic leukaemia being marketed in Ukraine and procured through international organisation contracted by the Ministry of Health of Ukraine
  • EBRD, as part of the international consortium of experts, on reviewing the pharmaceutical legislation, regulations and practices of regulatory authorities of Ukraine, drafting of new Law of Ukraine on Medicinal Products, and providing recommendations on the Ukrainian legislation alignment with the EU legislation and practices
  • An emerging European bio-robotics and bionic prosthetics company on regulatory, commercial and compliance matters, as well as market access issues, including the reimbursement system and public procurement requirements
  • A global leading Canadian medical cannabis company on regulatory requirements to import, registration and commercialising medical cannabis products in Ukraine

Publications

2026

2025

2024

2023

Memberships & Roles

  • 2018 – present time - Member of the Ethics Committee of the Ukraine Network of Integrity and Compliance
  • Since 2012 – a legal advisor to the Healthcare Committee of the European Business Association and the Association for Pharmaceutical Research and Development (APRaD), helping to guide the legislation in the pharmaceutical and medtech sectors in line with the European Union standards
  • 2009 – present time - Co-Chair of the Healthcare Committee, American Chamber of Commerce in Ukraine
  • 2020-2023 – member of the Public Oversight Council at the National Health Service of Ukraine, providing oversight and expert legal advice on healthcare reform
  • 2021-2025 - a legal advisor to the Animal Health Committees of the European Business Association (EBA) in Ukraine
  • 2006 – Advocate (Attorney-at-Law) Certificate, Kyiv City Qualification Disciplinary Bar Commission, Ukraine

Education

2006 – Master's in law Diploma (with Honours), National University of Kyiv-Mohyla Academy

Practice Areas
Commercial Dispute Resolution Antitrust, Competition and Trade Public Procurement Intellectual Property
sectors
Life Sciences & Healthcare Consumer Products

Further reading

  • CMS strengthens global life sciences offering with four-strong lawyer hire in Ukraine

Insights by Borys

See all Insights
Expert Guide International

CMS Expert Guide to advertising of medicines and medical devices

22 Jul 2026 2 min read
Publication Ukraine

Rebuilding Ukraine

16 Jul 2026 2 min read
Legal Update Ukraine

Ukraine moves forward with MDR and IVDR implementation

14 Jul 2026 4 min read
Publication Ukraine

Investing and Doing Business in Ukraine 2026

22 Jun 2026 2 min read
Back to top Back to top
You will now find all Law-Now content on CMS.law
Explore more
If you want to use third party tools, please enable personalisation cookies as part of your cookie preferences. You can change this setting at any time via the button below or in our Cookie Notice.